Drug Trial Radar · NCT05078866
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
Last checked: Nov 20, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
45
Actual
Start
Nov 10, 2022
Primary completion
Apr 16, 2025
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Oct 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase Ib/II trial evaluates the safety and effect of the Nous-209 vaccine in Lynch syndrome patients. Lynch syndrome is an inherited disorder in which affected individuals have a higher-than-normal chance of developing colorectal cancer and certain other types of cancer, often before the age of 50. In Lynch syndrome, errors in the genetic information inside cells are not properly corrected. When that happens, the cells produce new proteins called neoantigens. Neoantigens are recognized by the body's immune system as foreign, and the body tries to get rid of them. Nous-209 is a vaccine made with man-made copies of some of those neoantigens. This trial aims to see whether the Nous-209 vaccine is safe to give to patients with Lynch syndrome, whether people are able to take the Nous-209 vaccine without becoming too uncomfortable, and how the immune system of patients with Lynch syndrome respond to the Nous-209 vaccine. This trial may help researchers determine whether receiving Nous-209 have an effect on the development of polyps or tumors in the colon.
Conditions
- Colorectal Carcinoma
- Lynch Syndrome
Interventions
Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSPBiological
Given IM
Biospecimen CollectionProcedure
Undergo blood sample collection
Endoscopic BiopsyProcedure
Undergo endoscopy with biopsy
MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSPBiological
Given IM
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rates of grade 2/3 adverse events and symptom reactivity following vaccinationTime frame: Up to 12 months
- Rate of immunogenicity following vaccination (Cohort I)Time frame: Baseline and week 9
- Rate of immunogenicity following revaccination (Cohort II)Time frame: Weeks 52 and at 8 weeks after the last boost with MVA-209-FSP (corresponding to week 68 and week 60, for arm A and B, respectively)
- Rates of grade 2/3 adverse events and symptom reactivity following revaccination (Cohort II)Time frame: Up to 12 months
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
Fox Chase Cancer Center
Philadelphia, Pennsylvania
M D Anderson Cancer Center
Houston, Texas
University of Puerto Rico
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.